Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced the launch of Samsung Organoids, an advanced drug screening service designed to support clients in drug discovery and development. The announcement, made on June 15, 2025, represents a significant expansion of the company's service portfolio into preclinical research.
Advanced Organoid Technology for Drug Discovery
Samsung Organoids utilizes three-dimensional cell culture systems engineered to closely mimic human organs, offering clinically relevant insights to better understand specific drug responses and improve lead selection. These organoids are emerging as a new research model due to their high similarity to live tissues and potential applications in biomarker discovery and drug efficacy prediction.
The platform supports precision screening to predict patient responses, streamline preclinical development, and accelerate timelines toward investigational new drug (IND) filings through data-driven analysis of candidate molecules.
Comprehensive Preclinical Research Services
With this launch, Samsung Biologics expands its business to include preclinical research, with service offerings now spanning target discovery, lead selection, preclinical development, and clinical trial planning. Leveraging its expertise in development and manufacturing, the company will provide data-driven, multi-modal insights into the characteristics and mechanisms of candidate molecules.
By helping clients address challenges that may arise during the drug discovery phase, Samsung Biologics aims to enhance clinical success rates across the pharmaceutical development pipeline.
Strategic Vision for Personalized Medicine
"The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and creating new possibilities in personalized medicine," said John Rim, CEO and President of Samsung Biologics. "The addition of research services is a significant move for us to create added value for clients by supporting the drug life cycle from start to finish with thorough therapeutic analysis."
Samsung Biologics' Manufacturing Capabilities
Samsung Biologics operates as a leading CDMO, offering end-to-end integrated services that range from late discovery to commercial manufacturing. The company maintains a combined biomanufacturing capacity of 784 kL across five plants and leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.
The company operates a global network with facilities and offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region.
